These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 17366928)
1. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. Schwartzberg LS J Support Oncol; 2007 Feb; 5(2 Suppl 1):5-12. PubMed ID: 17366928 [TBL] [Abstract][Full Text] [Related]
2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Navari RM J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced nausea and vomiting. Lohr L Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612 [TBL] [Abstract][Full Text] [Related]
4. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. Slatkin NE J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383 [TBL] [Abstract][Full Text] [Related]
5. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Navari RM Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251 [TBL] [Abstract][Full Text] [Related]
6. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369 [TBL] [Abstract][Full Text] [Related]
7. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
8. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735 [TBL] [Abstract][Full Text] [Related]
9. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Balu S; Buchner D; Craver C; Gayle J Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990 [TBL] [Abstract][Full Text] [Related]
10. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Oo TH; Hesketh PJ Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016 [TBL] [Abstract][Full Text] [Related]
12. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting]. Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced nausea and vomiting: state of the art in 2006. Schwartzberg L J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138 [TBL] [Abstract][Full Text] [Related]
14. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263 [TBL] [Abstract][Full Text] [Related]
16. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Massaro AM; Lenz KL Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136 [TBL] [Abstract][Full Text] [Related]
17. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. Wickham R J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453 [TBL] [Abstract][Full Text] [Related]
18. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Navari RM Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing? Grunberg SM J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016 [TBL] [Abstract][Full Text] [Related]
20. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. Craver C; Gayle J; Balu S; Buchner D J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]